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Abstract
Diabetes mellitus (DM) is characterised by
alterations in the intrarenal renin-angiotensin
system (RAS). Insulin treatment may reverse
these changes by an unknown mechanism.We
aimed to verify the association between somatic
ACE with 136 kDa (sACE) and N-domain ACE
with 69 kDa (nACE) from Wistar (W) rat tissue
with DM.Three groups were studied: control
(CT), insulin treated diabetic (DT) and untreated
(D). ACE activity was determined using 
Hippuryl-His-Leu and Z-Phe-His-Leu as substrates.
In D group, urine ACE activity increased for both
substrates when compared with CT and DT,
despite the decreased activity of renal tissues.
Immunostaining of renal tissue demonstrated that
ACE is more strongly expressed in the proximal-
tubule of D than in the same nephron portion in
the other groups.Angiotensin (Ang) 1-7 and Ang
II are less expressed in DT group when
compared with CT and D. Ang II levels
decreased in the D and DT groups showed when
compared to the control. Ang 1-7 was detected
in all studied groups with low levels in DT.The
modulation of angiotensin peptides suggests that
sACE, nACE,ACE 2 and NEP could have important
functions in renal RAS regulation through a
counter-regulatory mechanism to protect the
kidney in diabetes mellitus.
Introduction
Diabetes mellitus (DM) is a chronic disease
caused by inhibition or deficiency in insulin
production by the pancreas due to destruction of
β-cells.1 This disease can cause vascular
complications such as hypertension, nephropathy
and retinopathy,2,3 but little is known about how
hyperglycaemia in diabetes can cause vascular
damage.4 The prevalence of hypertension and
other vascular problems increases in diabetic
patients as a result of alterations in the renin
angiotensin system (RAS).5
The RAS in diabetes has been studied in detail
including assessment of many components of this
system in the kidney.6-8 Furthermore, it has been
postulated that in diabetes there is a role for the
RAS in mediating many of the functional effects
such as changes in intraglomerular
haemodynamics9 as well as structural changes in
the diabetic kidney at both glomerular and
tubulointerstitium levels.9,10
There is strong evidence that angiotensin-
converting enzyme (ACE) activity is increased in
serum5,11-15 and tissues such as lung,11,12 ventricle,16
mesenteric artery,17 aorta and heart18 of STZ-
induced diabetic rats. Insulin treatment could
reverse some of these changes,19 but the
mechanism by which insulin treatment affects
ACE activity is still unknown.
ACE is a dipeptidyl carboxypeptidase which has
two active sites, the C and N-domains and is
involved in the metabolism of two major types of
vasoactive peptides. It converts the inactive
decapeptide angiotensin I (Ang I) to angiotensin
II (Ang II) which is a potent vasoconstrictor and
inactivates the vasodilators bradykinin and
kallidin.20,21 There are two isoforms of ACE: a
somatic isoform (150–180 kDa) which is
particularly abundant in the endothelium,22 and a
smaller germinal isoform (90–100 kDa) identical
to the C-terminal portion of endothelial ACE
except in the first 36 residues.23 A soluble isoform
of ACE which is derived from the membrane-
bound isoform by the action of secretases is also
present in serum24 and other body fluids such as
urine.25-27 
More recently, an ACE-related carboxypeptidase
(ACE 2) was identified. This enzyme has 42%
homology with ACE at the metalloprotease
catalytic domain28,29 but differs from it by having
only one enzymatic site. ACE 2 activity may
counterbalance Ang II promoting effects by
preventing Ang II accumulation in tissues.30-32
ACE 2 hydrolyses Ang I to Ang 1-9 and also Ang
II to Ang 1-7. Ang 1-9 in turn can be converted
to Ang 1-7 by neutral endopeptidase and prolyl
endopeptidase.
Two ACE isoforms with molecular weight of 190
and 65 kDa (N-domain ACE [nACE]) in the urine
of healthy subjects, and two isoforms of 90 and
65 kDa (both nACE) in the urine of hypertensive
patients, was observed by Casarini et al.25,26 The
same profile was obtained by Marques et al.33 in
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the urine of Wistar–Kyoto and Spontaneously
Hypertensive rats (SHR), and by Ronchi et al.34 in
different tissues of Wistar and SHR. In tissues of
Wistar rats the somatic ACE (sACE) presented a
molecular mass of 136 kDa and nACE 69 kDa.34
The nACE is able to hydrolyse Ang 1-7 which is
described as a specific substrate for this
enzyme.26 The current study was aimed to
associate the possible alterations in expression
and/or enzymatic activity of ACE forms with 136
and 69 kDa from Wistar rat tissue with renal
dysfunction in DM.
Methods
Wistar rats used in the present experiments were
obtained from the colony of Centro de
Desenvolvimento de Modelos Experimentais
(CEDEME), Escola Paulista de Medicina/
Universidade Federal de São Paulo, Brazil. The
Ethic Committee on Animal Experimentation
from Universidade Federal De São Paulo
approved this project.
Animal model 
Experiments were performed on 299–328 g male
Wistar rats. Diabetes was induced by a single
intravenous injection of streptozotocin (50
mg/Kg; Sigma, Chemical, St. Louis, MO). Before
the induction of DM, rats were kept in metabolic
cages with free access to tap water, and
measurement of their arterial blood pressure
(BP) and blood glucose levels were performed.
Only animals with plasma glucose concentration
> 250 mg/dL two days after induction of diabetes
were included in the study. Rats were divided
into three groups: 1) control (CT) rats, (n=4);
2) untreated diabetic rats (D) (n=3) and 3) insulin
treated diabetic rats (DT) (n=4) which were
treated daily with 1 unit of human NPH insulin
(Biohulin, Brazil). Eight weeks into the study and
two days before completion, the rats were
transferred into metabolic cages, urine was
collected and then the rats were sacrificed by
decapitation. The kidney was removed, washed
in saline phosphate buffer (PBS) and frozen at
-70ºC until analysis.
Measurement of the systolic blood pressure
and body weight 
Systolic blood pressure (SBP) and body weight
were measured in all groups twice weekly,
during the study. SBP was determined by tail-cuff
method and the Ohaus balance (Union, N. J.)
was used to determine the body weight.
Measurement of blood glucose and
proteinuria
Blood glucose levels were measured weekly
during the study, using the ADVANTAGE
(Roche, Swiss) equipment. Proteinuria was
determined using the 24-hour urine collected
two days before the animals were sacrificed
using the Kit Sensiprot (Labtest Diagnostica,
Brazil).
Protein determination 
Protein concentration was determined by the
Bradford35 method (Bio Rad Protein Assay Kit,
Bio Rad, USA) using bovine serum albumin as
standard, except when absorbance at 280 nm
was used for the chromatographic elution
profile.
Urine preparation  
Urine was collected during a period of 24 hours
from rats in metabolic cages and was processed
individually. The volume of urine was measured
and the pH was corrected to 8.0 with 1 mol/L
Tris buffer. Urine samples were submitted to
centrifugation (3,000 rpm) and the supernatant
was concentrated in Centricon (Millipore, USA)
and dialysed in the same equipment against 50
mmol/L Tris-HCl, pH 8.0, containing 150 mmol/L
NaCl, with the use of a 30-kDa molecular weight
exclusion membrane.
Tissue preparation 
Tissue was homogenised as described by
Oliveira et al.36 in 100 mmol/L phosphate buffer
(PB), pH 7.2, containing 340 mmol/L sucrose,
300 mmol/L NaCl (1 g tissue: 10 mL buffer) and
inhibitor PMSF (100 mmol/L). The homogenates
were centrifuged at 3,000 rpm, at 40ºC for 10 min
and the supernatant was frozen at -70ºC until
experimental use.
Enzymatic activity assay 
ACE catalytic activity was determined
fluorimetrically as described by Friedland and
Silverstein.37 An aliquot of kidney homogenate
(20 μL) and urine (50 μL) was incubated with a
200 μL assay solution containing 1 mmol/L
Z-Phe-His-Leu (ZPhe-HL) or 5 mmol/L Hippuryl-
His-Leu (HHL) in 100 mmol/L potassium
phosphate buffer, pH 8.3, with 300 mmol/L NaCl
and 0.1 mmol/L ZnSO4, for 10 minutes at 37ºC.
The enzymatic reaction was stopped by the
addition of 1.5 mL 280 mmol/L NaOH and
incubated with 100 μL o-phthaldialdehyde (20
mg/mL methanol) for 10 minutes. The
fluorescent reaction was stopped by the addition
of 200 μL 3N HCl. The liberated dipeptide HL
was measured fluorimetrically (360 nm excitation
and 500 nm emission) using a Hitachi fluorimeter
(Hitachi, Japan). The standard curve was
obtained using varying concentrations of L-HL in
the blank reaction mixture and it showed a linear
relation between relative fluorescence and HL
concentration.
Western blotting analysis 
Electrophoresis was performed on a 7.5% of slab
gel in presence of SDS according to the
Laemmli38 method, using 100 μg denatured and
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reduced protein. Electrotransference was
performed for 42 minutes at constant voltage
(40 V) using a nitrocellulose membrane (Hybond
ECL, GE Healthcare, Sweden). The membrane
was incubated in a 5% non-fat dry milk blocking
solution for four hours before overnight
incubation at room temperature (20ºC) with
monoclonal antibody 9B9 (Chemicon
International, USA) (diluted 1:1,000). The
subsequent steps were performed with the
streptavidin/phosphatase alkaline system (GE
Healthcare, Sweden) and the bands were revealed
using substrates NBT/BCIP as recommended by
the manufacturer (Bio Rad, USA).
Morphological analysis and
immunohistochemistry 
Renal rat tissues were fixed in 10% buffered
formol. The samples were submitted to a
conventional histology preparation and stained
with haematoxylin-eosin (H&E), periodic acid –
Schiff (PAS) and picro-sirius. The analysis of the
histological and morphological parameters to
detect the presence, or not, of glomerular
sclerosis, alterations in basal membrane, tubule,
mesangium and collagen were carried out by
means of optical microscopy.
The tissues were immunostained by the
peroxidase-antiperoxidase method with specific
antibodies against ACE (Chemicon International,
USA), Ang II and Ang 1-7, a generous gift from
Dr Preenie Senanayake, Eye Cole Institute,
Cleveland Clinic, Cleveland, Ohio, USA (1:100).
Briefly, kidney was rinsed with 0.05 mol/L Tris-
phosphate-saline buffer, pH 7.6. The micro-
dissected segments were incubated with the
primary antibody overnight at 22°C in a
humidified chamber followed by 60 minutes of
incubation at 22°C with the secondary antibody
(1:20) and then the peroxidase-antiperoxidase
complex (1:100) for 60 minutes at 22°C. The
immunoperoxidase reaction was visualised by
incubating the sections in 0.1% (wt/vol) 3,39-
diaminobenzidine and 0.03% (vol/vol) hydrogen
peroxide. The immunostained samples were
dehydrated and protected with coverslips and
haematoxylin counterstaining. Controls for the
immunostaining procedure were prepared by
omission of the first antibody.
Angiotensin quantification by HPLC 
Tissue was weighed and homogenised with 100
mmol/L PB, pH 7.2, containing 340 mmol/L
sucrose, 300 mmol/L NaCl and a mix of proteases
inhibitors ethylenediaminetetraacetic acid
tripotassium salt dihydrate (25 mM),
o-phenanthroline (0.44 mM), pepstatin A (0,12
mM) and 4-chloromercuribenzoic acid (1 mM). 20
mL of solvent was added to 1 g tissue followed
by centrifugation at 15,000 rpm for      20
minutes. The samples were concentrated in C18
Sep-Pak columns activated with methanol      (5
mL), tetrahydrofuran (5 mL), hexane (5 mL),
methanol (5 mL) and water (10 mL). The peptides
were eluted with ethanol, acetic acid and water
(90:4:6). The elutions were then lyophilised and
resuspended in 500 μL of mobile phase A: 5%
acetonitrile (50 mL) in 0.1% orthphosphoric acid
(1 mL). The peptide was separated in a reverse-
phase column Aquapore ODS 300 (250 x 4.6
mm), 7 μ, using the gradient 5–35% of mobile
phase B: 95% acetonitrile in H3PO4 0.1% in the
flow 1.5 mL/minutes for 40 minutes in the Milton
Roy System, constituted of two constaMetric 3000
pumps, a UV detector spectroMonitor 3100, a
programmer GM 4000 and a mixer. Synthetic
standards were used and peptide detection was
carried out at 214 nm. The results were expressed
in ng/mL and corrected by the weight of the
tissue.
Statistical analysis 
Data were presented as mean±SEM. Student t-test
and one-way analysis of variance (ANOVA), with
all pairwise comparisons followed by the Tukey
test, were used in this study. A value of p<0.05
was considered statistically significant.
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Table 1
Physiologic parameters of CT and D and DT groups.
Diabetes rats
CT D DT
Body weight (g) 338.9+15.6 315.4+16.2 365.4+13.6
Blood pressure (mmHg) 104.7+1.2 103.8+0.8 105.8+0.5
Blood glucose (mg/dL) 76.2+2.7 343.0+81.9* 56.0+14.0#
Urine volume (mL/24 hours) 7.2+0.8 61.2+12.9* 12.5+0.8#
Proteinuria (mg/24 hours) 8.1+0.9 26.4+1.5* 15.9+1.58*#
Key: Control (CT), insulin-untreated (D) and treated (DT) STZ diabetes rats. Values are mean+SE. *p<0.05: vs. CT, X+EP:
#  = p<0.05: vs. D.
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Results 
Physiologic parameters 
Data on body weight, BP, blood glucose, urine
volume and proteinuria in CT, D and DT rats are
shown in table 1. Body weight of the D rats was
reduced when compared to other groups. BP did
not alter in any of the groups. D rats presented
an increase (4-fold) in blood glucose levels and
in urine volume. The proteinuria was significantly
increased in both D and DT groups.
Morphological analysis 
Morphological analysis of the rat kidney
(figure 1) tissues from Wistar rats did not show
any of the alterations normally described in
diabetic nephropathy. We analysed also the basal
membrane, tubules, mesangium using two
different methods (data not shown) and did not
detect modifications in renal histology in the D
and DT groups.
ACE activity 
ACE activity was increased significantly in the
urine of the D group compared to the CT and DT
rats for both substrates. ACE activity for the ZPhe-
HL substrate in D increased when compared to
CT and DT groups being 26.9 and 1.71-fold,
respectively and for the HHL substrate  22.9 and
68.7-fold, respectively (figure 2).
Renal ACE activity was reduced slightly in the D
group when compared to other groups for both
substrates.
Expression of ACE protein in renal tissue 
The expression of ACE protein was determined
using Western blotting analysis. Proteins with
molecular mass of ~136 and 69 kDa were
expressed in renal tissue in CT, D and DT rats.
The expression of 69 kDa isoform was reduced
when compared to the 136 kDa isoform in renal
tissue (figure 3a and b).
Localisation of ACE, Ang 1-7 and Ang II
Immunohistochemistry was performed to localise
ACE, Ang 1-7 and Ang II in the kidney. The
highest expression of ACE was detected in the D
groups (figure 4). There was a lower expression
of Ang 1-7 in the D and DT groups. Ang II was
strongly stained in the D when compared to C
and DT groups.
Angiotensin quantification 
Ang 1-7, Ang II and Ang I concentration in total
homogenates was determined by HPLC. No
significant change in Ang 1-7 level was detected
in renal tissue in any of the studied groups. In D
and DT groups the levels of Ang II were
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Figure 1
Morphological analysis of renal tissue using HE colouration for the different groups of Wistar rats studied: Control (CT);
untreated diabetic rats (D); insulin-treated diabetic rats (DT). Magnification x 200.
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Figure 2
ACE activity (mU/mL) in urine and renal tissue of studied
animals at the end of eight weeks of treatment. CT = control
rats: D = untreated diabetic rats; DT = insulin-treated diabetic
rats. Results are mean±SE. *p<0.05: vs. CT # p<0.05: vs. D rats.
CO
PY
RIG
HT
 JR
AA
S L
IM
ITE
D
RE
PR
OD
UC
TIO
N 
PR
OH
IBI
TE
D
 at PONT UNIV CATH DE SAO PAULO on January 8, 2016jra.sagepub.comDownloaded from 
38
decreased in the renal tissue when compared to
CT. Ang I level did not alter in the different
groups analysed (figure 5).
Discussion 
DM is a serious risk factor for the development
of renal and cardiovascular disease.39 The RAS
has been implicated in the pathophysiology of
diabetic renal disease, based mainly upon the
activity of ACE inhibitors (ACE-Is) and Ang II
type I (AT1) receptor blockers to reduce
proteinuria and the progression of diabetic
glomerulosclerosis.40,41 
ACE is widely distributed in tissues. The
vasculature is one of the main locations of the
enzyme, where activity of ACE promotes vascular
responsiveness and cellular proliferation.42,43
There is evidence of a higher activity of this
enzyme in serum and some tissues such as
ventricle and lung11,12,16 in STZ-induced diabetic
rats, but also a reduction of activity has been
described in renal tissue.18
The objective of this study was to study the
association of somatic and nACE protein
expression and enzymatic activity in the renal
tissue homogenate of Wistar rats, in which DM
was induced by streptozotocin. We also aimed to
analyse ACE activity in urine and quantify the
Ang levels in tissues in the same model in
association with DM.
In our study the body weight of the rats was
reduced when we compared the CT to the DT
group (6.94% and 13.69%, respectively). The
blood glucose was significantly higher in the D
group (450%) when compared to the other
groups, similar to data found by de Cavanagh et
al.44 The urine volume was 8.5-fold higher in the
untreated diabetic rats than in the control group
as shown by Erman et al.11 Proteinuria is usually
seen as a marker of glomerular damage. Many
studies in different animal models suggest that
the proteinuria may contribute to the glomerular
and tubulointerstitial injury.45 The analysis of urine
24 hours after induction of DM demonstrated an
increase of proteinuria in the D and DT groups
(26.4 and 15.7 mg/24 hours, respectively) when
compared to control (8.1 mg/24 hours).11
The morphologic study did not show any
alteration in the renal tissue. We performed the
morphological analysis 60 days after DM
induction and probably this period of study was
not sufficient to detect renal damage in Wistar
rats. Siu et al. demonstrated that the number of
podocytes per glomerular section from rats and
mice with STZ-diabetes mellitus was reduced at
60 days only by 34%. Despite this early apparent
loss of podocytes in the STZ diabetic rat they
suggested that this model represents most animal
models of diabetic complications in failing to
develop classic changes of human diabetic
nephropathy in the early stages of the
development of diabetes.46
Diabetes has been associated with the elevated
activity of ACE in humans.47 Mezzano et al.48
described that in patients with diabetic
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Figure 3
a: Western blotting analysis of ACE protein expression in renal tissue: 1 - control (CT); 2 - untreated diabetic (D); 3 - insulin-
treated diabetic (DT) rats; standards (St) rainbow. Both isoforms were detected with the molecular weight of 136 and 69 kDa
in all groups. b: Relative density of ACE protein isoforms in the different groups. Data is expressed as mean±SE. 
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nephropathy the components of RAS are
modified in the renal compartments showing
elevated local production of Ang II and
activation of the tubule cells. These observations
are in concordance with the results demonstrated
by this study, where an increase of ACE activity
was detected in the urine of the untreated
diabetic rats when compared to other groups for
both substrates (ZPhe-HL and HHL). The ZPhe-
HL substrate is related to the N-domain activity of
ACE while the HHL is described as a specific
substrate for the C-domain portion. We  suggest
that nACE, despite its reduced expression, is
more active in this model based on the high
activity levels detected using ZPhe-HL. The
decreased activity found for HHL could be
attributed to sACE. The DT group showed a
statistical significant reduction in urinary ACE
activity when compared to D rats also for both
substrates. This finding emphasises the
potentially important role of renal ACE (somatic
and N-domain) in the aetiology of the
complications in diabetes.
Renal ACE activity using ZPhe-HL and HHL was
decreased in the untreated diabetic rats when
compared to other groups, which is consistent
with previous studies8,18,49 where redistribution of
ACE in the diabetic kidney has been shown
indicating that ACE activity in the proximal
tubule was reduced. Despite the reduction of
ACE in renal tissue attributed to the proximal
tubule, the increase of urinary ACE could be
supported by the high ACE production in the
collecting duct as described by Casarini et al.50 in
micropuncture studies, and by Quinto et al.51 in
inner medullary connecting duct, suggesting a
new site of ACE regulation in diabetes.
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Figure 4
Localisation of ACE, Ang 1-7 and Ang II in the renal tissue using monoclonal antibody against ACE and polyclonal for Ang 1-7
and Ang II. Original magnification x 200.
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Figure 5
Qualification of Ang 1-7, Ang II and Ang I levels in kidney
tissue from: CT = control (n=4); D = untreated diabetic (n+3);
DT = insulin-treated diabetic (n=4) rats measured by HPLC.
Data shown as mean±SE. *p<0.05: vs. CT.
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The molecular mass of ACE isoforms from renal
tissues (136 and 69 kDa) of Wistar rats were
similar to the recent findings described in healthy
human urine,25,26 normotensive rat urine33 and in
different tissues of Wistar rats by Ronchi et al.34 The
protein expression of 136 and 69 kDa enzymes
showed no statistically significant decrease in the
renal tissue of D and DT groups when compared
to the C which was similar to the results found for
ACE activity. The isoform with a molecular weight
of 90 kDa and considered a genetic marker of
hypertension detected in SHR tissues was not
expressed in the  renal tissue of Wistar rats,
confirming the results described by our group.34
ACE was detected in complete kidney sections
from untreated rats in the proximal tubule and
glomerulus. In the same sections we detected
Ang 1-7 and Ang II in untreated and treated
animals confirming our previous results in the
quantification of these peptides.
When we quantified the angiotensin peptides,
Ang I was increased in renal tissue of D and DT
groups indicating a probable activation of renin,
similar to the data described in the same model
by Anderson et al.8 Ang 1-7 levels are similar in
all studied groups though being decreased non-
significantly D and DT.
This finding could be supported by the lower
levels of Ang II in the D and DT groups
indicating the action of prolyl endopeptidase or
ACE 2 upon this peptide to produce Ang 1-7 that
could be hydrolysed by nACE that is activated in
this model. The treatment of diabetic animals
decreased production of the peptides when
compared with D but did not normalise the levels
to those of the control, suggesting that other
mechanisms in diabetes need to be further
studied. The presence of Ang 1-7 could protect
the kidney against damage by maintaining
adequate natriureses and diureses as described
by Santos et al.52
This is the first description of the presence of Ang
1-7 in the kidney in favouring ACE 2 or prolyl
endopeptidase activation in STZ-induced diabetic
rats. The increase in Ang I levels as a result of
renin activation suggests an action of NEP upon
this peptide, contributing also to the Ang 1-7
formation to counterbalance the action of Ang II
to protect the organ against damage in DM. The
presence of nACE with 69 kDa could contribute
to the Ang 1-7 degradation to Ang 1-5.
Our observations are consistent with a
modulation of angiotensin peptides and enzymes
responsible for their production and degradation.
The roles of this modulation represent new
avenues for future investigation of the
mechanisms involved in these pathways.
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